Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloproliferative Neoplasm (MPN) and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for JAK2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | JAK2 Kinase Domain (WT & V617F Mutant) Recombinant Protein High purity (>95%), Endotoxin <1EU/µg, Sequence Verified, ATP-binding site integrity preserved. |
View JAK2 Products |
| Gene Delivery | JAK2 Promise-ORF / Lentivirus Particles Full-length ORF for stable Ba/F3 or HEK293 cell line construction, Titer >10^8 TU/ml. |
View JAK2 Products |
| Benchmark Ab | Anti-JAK2 Recombinant Rabbit mAb (Total & Phospho-Specific, or Pan-specific Clone) Sequence-defined positive control for Western Blot, IHC, and target engagement studies. |
View JAK2 Products |
| Validator | JAK2 siRNA Set (3 unique targets) For knockdown verification and off-target assessment in cellular proliferation assays. |
View JAK2 Products |
| Related Target A | JAK1 Paralog kinase; critical for JAK2 selectivity profiling and off-target liability assessment. |
View JAK1 Products |
| Related Target B | JAK3 Immunospecificity screening (T-cell sparing assessment). |
View JAK3 Products |
| Related Target C | TYK2 Additional paralog for complete JAK family selectivity profiling. |
View TYK2 Products |
| Related Target D | MPL (Thrombopoietin Receptor) Upstream activator in MPN pathogenesis; synergistic pathway and resistance mechanism analysis. |
View MPL Products |
| Related Target E | STAT3 Downstream primary effector; essential for validating functional target engagement in cell-based assays. |
View STAT3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allele-specific V617F mutant vs WT JAK2 inhibition | WT & V617F Mutant Kinase Domain proteins (>95% purity, Endotoxin <1 EU/µg) for differential IC50 and binding determination. |
| JAK paralog selectivity (JAK1/JAK3/TYK2 off-target) | Homolog panel proteins (JAK1, JAK3, TYK2) strictly sequence-verified by mass spectrometry; human orthologs available with identical HEK293 expression systems for consistent screening. |
| Resistance mutation profiling | Exon 12 mutant library available (N542-E543del, K539L) for preemptive resistance testing; also covers acquired mutations like Y931C, I871V. |
| Lack of physiologic cellular assay controls | Full-length JAK2 ORF Lentivirus (high titer >10^8 TU/ml) for stable cell line generation; preserves native conformation and adaptor interactions. |
| False positives / Target engagement verification | Validated JAK2 siRNA included for knockdown specificity checks and phenotypic correlation; sequence-verified control antibodies minimize false positives. |
Global Clinical Landscape & Future Outlook
The race for JAK2 therapeutics is intensifying, with major players shifting focus from pan-JAK inhibitors to highly selective JAK2 modalities that spare JAK1 to reduce myelosuppression. As first-generation ATP-competitive inhibitors such as ruxolitinib and fedratinib face patent cliffs, generic entry, and resistance limitations (e.g., acquired mutations Y931C, I871V), the next wave of R&D is targeting the unique JH2 pseudokinase domain conformation of JAK2 V617F to achieve allele-specific suppression. Concurrently, emerging PROTAC and molecular glue programs aim to induce JAK2 degradation rather than mere catalytic inhibition, requiring full-length cellular systems for binary complex detection. Combination therapies with BET inhibitors, BCL-2 inhibitors, or PI3K inhibitors are also advancing to overcome single-agent resistance. The competitive landscape includes Incyte/Novartis (ruxolitinib), BMS (fedratinib), CTI BioPharma (pacritinib), GSK (momelotinib), and numerous Chinese biotechs (e.g., Chipscreen Biosciences) developing next-generation selective JAK2 inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-JAK Inhibitor (Small Molecule, Type I/II ATP-competitive) | Incyte, Novartis, BMS | Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Autoimmune | Paralog Selectivity Panel (Need JAK1/JAK2/JAK3/TYK2 ortholog proteins) |
| JAK2-Selective Inhibitor (Small Molecule) | CTI BioPharma, GSK/Sierra Oncology, Nurix, Chinese biotechs | Refractory Myelofibrosis, Essential Thrombocythemia, Solid tumors | Mutant vs WT Differential Assay (Need V617F & WT recombinant kinases) |
| Allosteric Inhibitor (JH2-targeting) | Various biotechs | Myelofibrosis, JAK2-amplified solid tumors | Conformational binding assay (Need full-length JAK2 protein including pseudokinase domain) |
| PROTAC / Degrader | Arvinas, C4 Therapeutics, BMS | Relapsed/Refractory MPNs, JAK2-Driven Solid Tumors | Cellular Degradation Assay (Need Full-length JAK2 Lentivirus & stable lines; specific Anti-JAK2 Abs) |
| Combination Therapy (JAK2i + BET/Bcl-xL/PI3K) | Constellation (MorphoSys), AbbVie | Myelofibrosis, MPN | Pathway Analysis (Need comprehensive target network tools: STAT3/STAT5 Lentivirus, dual-target cell models) |
Live JAK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Key Mutations and Functional Domains of JAK2
Based on UniProt O60674, JAK2 contains three functional domains: FERM, atypical SH2, and Protein Kinase domain (JH1). Key somatic mutations include rs56118985, a mutation found in ovarian serous carcinoma sample (somatic), and rs55667734. The most clinically relevant driver mutation is V617F in the JH2 pseudokinase domain, which constitutively activates JAK2 and drives MPN pathogenesis.
Note: TarMart provides high-purity WT and V617F mutant kinase domain proteins for differential screening, along with full-length ORF lentivirus for cellular assays and pan-JAK selectivity panels.